State of Michigan Retirement System Buys Shares of 12,002 Enovis Co. (NYSE:ENOV)

State of Michigan Retirement System purchased a new position in shares of Enovis Co. (NYSE:ENOVGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,002 shares of the company’s stock, valued at approximately $660,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. M&T Bank Corp acquired a new position in Enovis during the second quarter worth $137,000. Boenning & Scattergood Inc. bought a new position in shares of Enovis in the 2nd quarter valued at approximately $210,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Enovis in the 2nd quarter worth approximately $261,000. TAGStone Capital Inc. bought a new stake in Enovis during the second quarter worth approximately $288,000. Finally, Citadel Investment Advisory Inc. acquired a new position in Enovis during the second quarter valued at approximately $288,000. Institutional investors own 89.40% of the company’s stock.

Enovis Trading Down 3.3 %

Shares of NYSE ENOV opened at $53.92 on Tuesday. Enovis Co. has a one year low of $43.88 and a one year high of $157.71. The business has a fifty day simple moving average of $49.33 and a 200 day simple moving average of $55.74. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of 112.34, a PEG ratio of 1.18 and a beta of 2.03.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ENOV. Robert W. Baird decreased their price objective on shares of Enovis from $73.00 to $68.00 and set an “outperform” rating for the company in a report on Thursday, November 3rd. Canaccord Genuity Group assumed coverage on Enovis in a research report on Monday, September 12th. They issued a “buy” rating and a $67.00 price target on the stock. Jefferies Financial Group began coverage on Enovis in a research report on Wednesday, October 12th. They set a “buy” rating and a $60.00 price objective for the company. Evercore ISI started coverage on Enovis in a report on Monday, September 12th. They issued an “outperform” rating and a $68.00 target price on the stock. Finally, The Goldman Sachs Group initiated coverage on Enovis in a report on Tuesday, October 11th. They set a “buy” rating and a $57.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $63.50.

Enovis Company Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Further Reading

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.